Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
12.91
Dollar change
+0.10
Percentage change
0.78
%
IndexRUT P/E- EPS (ttm)-2.16 Insider Own59.11% Shs Outstand41.13M Perf Week-1.15%
Market Cap640.98M Forward P/E- EPS next Y-3.10 Insider Trans1.94% Shs Float20.30M Perf Month15.89%
Income-90.80M PEG- EPS next Q-0.70 Inst Own39.57% Short Float4.99% Perf Quarter-15.34%
Sales0.00M P/S- EPS this Y-47.15% Inst Trans- Short Ratio7.14 Perf Half Y89.02%
Book/sh6.61 P/B1.95 EPS next Y-5.79% ROA-27.78% Short Interest1.01M Perf Year-16.76%
Cash/sh6.82 P/C1.89 EPS next 5Y- ROE-29.11% 52W Range5.85 - 17.44 Perf YTD50.12%
Dividend Est.- P/FCF- EPS past 5Y- ROI-27.68% 52W High-25.97% Beta2.03
Dividend TTM- Quick Ratio18.06 Sales past 5Y0.00% Gross Margin- 52W Low120.68% ATR (14)0.69
Dividend Ex-Date- Current Ratio18.06 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)49.58 Volatility3.28% 5.49%
Employees28 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price33.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-127.38% Payout- Rel Volume0.45 Prev Close12.81
Sales Surprise- EPS Surprise-4.79% Sales Q/Q- EarningsMay 09 BMO Avg Volume141.92K Price12.91
SMA200.26% SMA501.26% SMA20018.28% Trades Volume63,666 Change0.78%
Date Action Analyst Rating Change Price Target Change
Apr-02-24Initiated Goldman Buy $30
Mar-07-23Initiated Wells Fargo Overweight $27
Mar-07-23Initiated Stifel Buy $45
Mar-07-23Initiated Guggenheim Buy $32
Mar-07-23Initiated Evercore ISI Outperform
Mar-07-23Initiated Credit Suisse Outperform $40
Mar-07-23Initiated BofA Securities Buy $39
May-13-24 11:45AM
May-09-24 11:56AM
07:00AM
May-06-24 08:00AM
May-02-24 08:00AM
12:16AM Loading…
Apr-05-24 12:16AM
Mar-22-24 10:51AM
Mar-21-24 11:53AM
09:11AM
07:00AM
Mar-13-24 04:05PM
Feb-08-24 08:00AM
Jan-29-24 04:05PM
Jan-17-24 12:00PM
Jan-04-24 04:05PM
04:05PM Loading…
Dec-21-23 04:05PM
Nov-12-23 09:22AM
Nov-11-23 11:30AM
Nov-09-23 04:05PM
Nov-07-23 05:12PM
04:05PM
Nov-02-23 10:00AM
Oct-31-23 04:05PM
Oct-13-23 04:10PM
Sep-19-23 04:00PM
Sep-14-23 04:05PM
Sep-11-23 04:05PM
Sep-10-23 07:47AM
07:45AM
Sep-09-23 05:00AM
04:05PM Loading…
Sep-05-23 04:05PM
09:55AM
Aug-29-23 04:05PM
Aug-22-23 05:45PM
Aug-07-23 04:05PM
Jul-31-23 04:05PM
Jul-17-23 04:01PM
Jun-09-23 08:04AM
May-31-23 08:00AM
May-15-23 04:01PM
May-10-23 08:39AM
May-02-23 08:00AM
May-01-23 08:00AM
Apr-27-23 04:47PM
Mar-15-23 04:01PM
Mar-04-23 04:30PM
Mar-01-23 04:05PM
Feb-20-23 08:00AM
Feb-17-23 12:08PM
Feb-14-23 04:01PM
Feb-10-23 05:16PM
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rodman David MalcomChief Medical OfficerMay 13 '24Option Exercise0.8411,3669,56678,363May 15 04:43 PM
Rodman David MalcomChief Medical OfficerMay 09 '24Option Exercise1.0810010867,097May 10 04:17 PM
Rodman David MalcomChief Medical OfficerMay 09 '24Sale15.001001,50066,997May 10 04:17 PM
Rodman David MalcomChief Medical OfficerApr 12 '24Option Exercise1.086,3496,85766,997Apr 15 04:24 PM
Rodman David MalcomChief Medical OfficerApr 11 '24Option Exercise0.545,0172,70960,648Apr 15 04:24 PM
Rodman David MalcomChief Medical OfficerMar 12 '24Option Exercise1.086,3486,85655,631Mar 13 05:35 PM
Rodman David MalcomChief Medical OfficerMar 11 '24Option Exercise0.545,0172,70949,283Mar 13 05:35 PM
Rodman David MalcomChief Medical OfficerFeb 12 '24Option Exercise0.8411,3669,56644,266Feb 13 04:08 PM
Samsara BioCapital GP, LLC10% OwnerFeb 12 '24Buy13.50555,5557,499,9925,074,916Feb 14 09:06 PM
Rodman David MalcomChief Medical OfficerJan 12 '24Option Exercise1.086,3486,85632,900Jan 12 04:01 PM
Rodman David MalcomChief Medical OfficerJan 11 '24Option Exercise0.545,0172,70926,552Jan 12 04:01 PM
Rodman David MalcomChief Medical OfficerDec 11 '23Option Exercise0.545,0182,71020,069Dec 12 05:08 PM
Congleton JonChief Executive OfficerNov 22 '23Buy5.974,25025,3561,049,068Nov 27 04:01 PM
Rodman David MalcomChief Medical OfficerNov 13 '23Option Exercise0.545,0172,70915,051Nov 14 06:18 PM
Rodman David MalcomChief Medical OfficerNov 03 '23Option Exercise0.5410,0345,41810,034Nov 07 05:15 PM
Congleton JonChief Executive OfficerSep 06 '23Buy12.082,25027,1801,044,818Sep 08 08:49 AM
Congleton JonChief Executive OfficerAug 17 '23Buy12.102,25027,2251,042,568Aug 21 04:03 PM
Rodman David MalcomChief Medical OfficerAug 11 '23Option Exercise0.80157,091125,96780,909Aug 11 07:11 PM
Congleton JonChief Executive OfficerAug 11 '23Buy12.892,00025,7801,040,318Aug 11 07:11 PM
Rodman David MalcomChief Medical OfficerAug 11 '23Sale12.81157,0912,012,3360Aug 11 07:11 PM
Rodman David MalcomChief Medical OfficerAug 10 '23Option Exercise0.5474,62540,29874,625Aug 11 07:11 PM
Rodman David MalcomChief Medical OfficerAug 10 '23Sale13.1674,625982,0650Aug 11 07:11 PM